VIB
VC Fund
Gent, Belgium
VIB is a VC fund in Gent focused on Biotechnology and Health Care. VIB, a Belgium-based life sciences research institute, performs research for pharmaceutical, agricultural, and industrial applications.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries VIB invests in
Stages VIB invests in
Countries VIB invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Seed
- $3.1M–$11M
- Series A
- $6.8M–$84M
- Series B
- $4.7M–$65M
Investment Focus
Industry
- Biotechnology 14 (50%)
- Health Care 6 (21%)
- Therapeutics 5 (18%)
- Pharmaceutical 4 (14%)
- Medical 3 (11%)
Stage
- Series A 9 (32%)
- Series B 6 (21%)
- Seed 5 (18%)
- Funding Round 3 (11%)
- Series C 1 (4%)
Country
- Belgium 15 (54%)
- Brazil 1 (4%)
- Denmark 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erwin Sablon
Expert Scientist Diagnostics & Biomarkers
|
Expert Scientist Diagnostics & Biomarkers | Total investments: 0 | Find email | |
Isabel Vercauteren
Entrepreneur in Residence
|
Entrepreneur in Residence | Total investments: 0 | Find email | |
Jan Steyaert
Groupleader; Director
|
Groupleader; Director | Total investments: 0 | Find email | |
Jerome Van Biervliet
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Jo Bury
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties. | $11.2M / Seed / Jun 16, 2026 | ||
| Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $14.1M / Post-IPO Equity / May 06, 2026 | ||
| MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M / Series B / Sep 04, 2025 | ||
| Animal Health Company | $11.8M / Series B / Jul 01, 2025 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | ||
| Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M / Series B / Jul 26, 2024 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | ||
Protealis
|
Sustainable plant proteins for Europe | $23.9M / Series B / Jan 23, 2024 | |
|
Tanai Therapeutics
|
Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications. | $3.1M / Seed / Dec 06, 2023 | |
| Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases. | $43.5M / Series A / May 15, 2023 | ||
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does VIB invest in?
VIB invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is VIB's check size?
VIB typically joins rounds of $3.1M–$11M at Seed, $6.8M–$84M at Series A and $4.7M–$65M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VIB participates in.
How do I contact VIB?
Public channels for VIB include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VIB?
The team at VIB includes Erwin Sablon (Expert Scientist Diagnostics & Biomarkers), Isabel Vercauteren (Entrepreneur in Residence) and Jan Steyaert (Groupleader; Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
